Cystathionine‐gamma‐lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy
Mélanie Lancien, Lucile Gueno, Sonia Salle, Emmanuel Mérieau, Gaëlle Bériou, Tuan Huy Nguyen, Ahmed Abidi, Nahzli Dilek, Pierre Solomon, Jérémie Poschmann, Olivier Michielin, Romain Vuillefroy de Silly, Bernard Vanhove, Cédric Louvet
Abstract
Abstract T cells could be engineered to overcome the aberrant metabolic milieu of solid tumors and tip the balance in favor of a long‐lasting clinical response. Here, we explored the therapeutic potential of stably overexpressing cystathionine‐gamma‐lyase (CTH, CSE, or cystathionase), a pivotal enzyme of the transsulfuration pathway, in antitumor CD8 + T cells with the initial aim to boost intrinsic cysteine metabolism. Using a mouse model of adoptive cell transfer (ACT), we found that CTH‐expressing T cells showed a superior control of tumor growth compared to control T cells. However, contrary to our hypothesis, this effect was not associated with increased T cell expansion in vivo or proliferation rescue in the absence of cysteine/cystine in vitro. Rather than impacting methionine or cysteine, ACT with CTH overexpression unexpectedly reduced glycine, serine, and proline concentration within the tumor interstitial fluid. Interestingly, in vitro tumor cell growth was mostly impacted by the combination of serine/proline or serine/glycine deprivation. These results suggest that metabolic gene engineering of T cells could be further investigated to locally modulate amino acid availability within the tumor environment while avoiding systemic toxicity.